ad
This Article
Right arrow Full Version
Services
Right arrow E-mail this link to a friend
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Section 1
Section 2
Section 3
Section 4
Section 5
Appendices
Right arrow Earn CME - What's This?
Related Collections
Right arrowRelated Article

The following text is from an archived Red Book® edition and may not reflect current recommendations or information. To view the current edition, click here.

The first 20% of the full text of this section appears below.

Section 4. Antimicrobial Agents and Related Therapy

INTRODUCTION

Fluoroquinolones

Use of fluoroquinolones (eg, ciprofloxacin, levofloxacin, lomefloxacin, gatifloxacin, gemifloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin) generally is contraindicated, according to FDA-approved product labeling, in children and adolescents younger than 18 years of age, because fluoroquinolones have been shown to cause cartilage damage in every juvenile animal model tested at doses that approximate those needed to be therapeutic. The mechanism for this damage is unknown. Pefloxacin, a fluoroquinolone that had been used extensively in France, causes adverse musculoskeletal effects in children and adults and is not available in the United States.

Ciprofloxacin and levofloxacin are the fluoroquinolones that . . . [Go to Full Text]


Related Article

Tables of Antibacterial Drug Dosages
Red Book 2006 2006: 750-765. [Extract] [Full Text]